Idogen AB
BioTech/Drugs - Lund, Lund, Sw
Idogen AB Employees
Idogen AB Details
Idogen develops tolerogenic cell therapies which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement. The treatment method comprises cells from the patient's blood being programmed to dendritic cells with the capacity to specifically counteract the adverse immune reaction. The company's technology platform has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com
Idogen AB Technologies
Retargeting
Facebook Custom Audiences
Email Providers
Outlook
CMS
WordPress.org
Fonts
Google Font API
Social Login
Facebook Login (Connect)
Other
Microsoft Office 365